Skip to main content
SpringerLink
Log in

Leserbrief zu Hilscher HJ. Schmerzmedizin 2018; 34 (4): 24–27

„Mögliche Vorteile von Methadon viel zu positiv dargestellt“

  • Fortbildung
  • Leserbriefe
  • Published:
Schmerzmedizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Raynor K et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Molecular Pharmacology. 1994;45(2):330–4

    CAS  Google Scholar 

  2. Ebert B et al. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neuroscience Letter. 1995;187:165–8

    Article  CAS  Google Scholar 

  3. Gorman AL et al. The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters. 1997;223:5–8

    Article  CAS  Google Scholar 

  4. Matsui A, Williams JT. Activation of micro-opioid receptors and block of Kir3 potassium channels and NMDA receptor conductance by L- and D-methadone in rat locus coeruleus. British journal of pharmacology. 2010;161(6):1403–13

    Article  Google Scholar 

  5. Codd EE et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. Journal of Pharmacology and Experimental Therapeutics. 1995;274:1263–70

    CAS  Google Scholar 

  6. Kafami L et al. Methadone diminishes neuroinflammation and disease severity in EAE through modulating T cell function. Journal of neuroimmunology. 2013;255(1-2):39–44

    Article  CAS  Google Scholar 

  7. Hendra T et al. Fatal methadone overdose. British Medical Journal. 1996;313:481–2

    Article  CAS  Google Scholar 

  8. Chatham MS et al. Dose ratios between high dose oral morphine or equivalents and oral methadone. Journal of palliative medicine. 2013;16(8):947–50

    Article  Google Scholar 

  9. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliative medicine. 2011;25(5):504–15

    Article  Google Scholar 

  10. Benitez-Rosario MA et al. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. Journal of Pain and Symptom Management. 2009;37(6):1061–8

    Article  CAS  Google Scholar 

  11. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Medicine. 2008;9(5):595–612

    Article  Google Scholar 

  12. Walker PW et al. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? Journal of palliative medicine. 2008;11(8):1103–8

    Article  Google Scholar 

  13. Tse DM et al. An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliative medicine. 2003;17(2):206–11

    Article  Google Scholar 

  14. Ripamonti C et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? Journal of Clinical Oncology. 1998;16(10):3216–21

    Article  CAS  Google Scholar 

  15. Freye E. Opioide in der Medizin. 9 ed: Springer Verlag; 2016. p. S. 84-5

  16. Lugo RA et al. Pharmacokinetics of methadone. Journal of Pain and Palliative Care Pharmacotherapy. 2005;19(4):13–24

    Article  Google Scholar 

  17. Fisher K et al. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. Journal of Pain and Symptom Management. 2004;28(6):619–25

    Article  CAS  Google Scholar 

  18. Hagen NA et al. A formal feasibility study of sublingual methadone for breakthrough cancer pain. Palliative medicine. 2010;24(7):696–706

    Article  Google Scholar 

  19. Takase N et al. Methadone for Patients with Malignant Psoas Syndrome: Case Series of Three Patients. Journal of palliative medicine. 2015;18(7):645–52

    Article  Google Scholar 

  20. Sugiyama Y et al. A Retrospective Study on the Effectiveness of Switching to Oral Methadone for Relieving Severe Cancer-Related Neuropathic Pain and Limiting Adjuvant Analgesic Use in Japan. Journal of palliative medicine. 2016;19(10):1051–9

    Article  Google Scholar 

  21. McNicol ED et al. Methadone for neuropathic pain in adults. The Cochrane database of systematic reviews. 2017;5:Cd012499

    Google Scholar 

  22. Davis MP et al. When opioids cause pain. Journal of Clinical Oncology. 2007;25(28):4497–8

    Article  Google Scholar 

  23. El Osta B et al. Intractable pain: intoxication or undermedication? Journal of palliative medicine. 2007;10(3):811–4

    Article  Google Scholar 

  24. Gießelmann K. Onkologie: Methadon wirkt unterschiedlich. Deutsches Ärzteblatt. 2018;115(11):480

    Google Scholar 

  25. Wirz S et al. Onkologie: Zu viele Fragen offen. Deutsches Ärzteblatt. 2018;115(23):A 1134

    Google Scholar 

  26. Bart G et al. Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug and alcohol dependence. 2014;145:185–93

    Article  CAS  Google Scholar 

  27. Ojanpera I et al. Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database. International journal of legal medicine. 2016;130(5):1209–16

    Article  Google Scholar 

  28. Ray WA et al. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA internal medicine. 2015;175(3):420–7

    Article  Google Scholar 

  29. Arznei-Telegramm. Methadon gegen Krebs? 2017 [Available from: www.arznei-telegramm.de/html/htmlcontainer.php3?produktid=049_02&artikel=1706049_02k

  30. Hofbauer H et al. Einsatz von Methadon zur Unterstützung der onkologischen Therapie? Der Schmerz. 2017;31(1):2–4

    Article  CAS  Google Scholar 

  31. Neuroonkologische Arbeitsgemeinschaft in der Deutschen Krebsgesellschaft (NOA) und Deutsche Gesellschaft für Neurologie (DGN). Gliomtherapie mit Methadon: bisher nur experimentell getestet — Wirkung beim Menschen völlig unklar 2015 [Available from: www.dgn.org/images/red_pressemitteilungen/2015/150326_Stellungnahme_NOA_DGN_Methadon_bei_Glioblastom_final.pdf

  32. DGHO (Deutsche Gesellschaft für Hämatologie und Onkologie). Methadon bei Krebspatienten: Zweifel an Wirksamkeit und Sicherheit. Stellungnahme der DGHO DGHO Onkopedia Leitlinien2017 [Available from: www.dgho.de/informationen/stellungnahmen/gute-aerztliche-praxis/DGHO_Stellungnahme_Methadon%2020170426_.pdf

  33. Lev R et al. Methadone related deaths compared to all prescription related deaths. Forensic science international. 2015;257:347–52

    Article  CAS  Google Scholar 

  34. Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief — United States, 1999-2010. Morbidity and Mortality Weekly Report (MMWR). 2012;61(26):493-7

  35. Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF) DKeVDuDKD, editor. S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Tumorerkrankung2015

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Palliativmedizin, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland

    Constanze Rémi MSc (Fachapothekerin für Klinische Pharmazie)

  2. http://www.springermedizin.de

    Claudia Bausewein & Lukas Radbruch

Authors
  1. Constanze Rémi MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Bausewein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lukas Radbruch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Constanze Rémi MSc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rémi, C., Bausewein, C. & Radbruch, L. „Mögliche Vorteile von Methadon viel zu positiv dargestellt“. Schmerzmed. 34, 21–23 (2018). https://doi.org/10.1007/s00940-018-0888-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00940-018-0888-1

Search

Navigation